ResMed, Inc.

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 01:30:01 12/09/2024 am IST			5-day change	1st Jan Change
252.92 ^USD	+0.02%		+3.34%	+47.03%

11/09	ResMed Insider Sold Shares Worth $3,646,950, According to a Recent SEC Filing	MT
06/09	Resmed Insider Sold Shares Worth $479,800, According to a Recent SEC Filing	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about ResMed, Inc.

ResMed Insider Sold Shares Worth $3,646,950, According to a Recent SEC Filing	11/09	MT
Resmed Insider Sold Shares Worth $479,800, According to a Recent SEC Filing	07/09	MT
Transcript : ResMed Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:00 AM	04/09
Needham Downgrades ResMed to Hold From Buy	04/09	MT
ResMed Elects Christopher DelOrefice to the Board	16/08	CI
Resmed Insider Sold Shares Worth $2,166,000, According to a Recent SEC Filing	14/08	MT
Resmed Insider Sold Shares Worth $3,145,905, According to a Recent SEC Filing	09/08	MT
Resmed Insider Sold Shares Worth $10,419,552, According to a Recent SEC Filing	07/08	MT
UBS Adjusts Price Target on ResMed to $225 From $210, Maintains Neutral Rating	05/08	MT
Recession Fears Drag Australian Shares to More than Two-Month Low	05/08	MT
ResMed Shares Hit 52-Week High After Reporting Strong Results on Friday	05/08	MT
RBC Adjusts ResMed's Price Target to $206 From $204, Keeps Sector Perform Rating	02/08	MT
Mizuho Securities Adjusts ResMed Price Target to $230 From $220	02/08	MT
KeyBanc Adjusts Price Target on ResMed to $251 From $238	02/08	MT
Jefferies Adjusts Price Target on ResMed to $200 From $180	02/08	MT
JPMorgan Adjusts Price Target on ResMed to $240 From $225, Maintains Overweight Rating	02/08	MT
Weak US Manufacturing Data Drag Down Australian Shares	02/08	MT
ResMed Fiscal Q4 Revenue Rises 9%, Net Income Up 27%; Lifts Dividend	02/08	MT
ResMed Reports Fiscal Q4 Revenue Up 9% to $1.22 Billion, EPS of $1.98	02/08	MT
ResMed Fiscal Q4 Non-GAAP Earnings, Revenue Rise	02/08	MT
ResMed meets estimates on steady demand for its sleep apnea devices	02/08	RE
ResMed Seeks Acquisitions	02/08	CI
Transcript : ResMed Inc., Q4 2024 Earnings Call, Aug 01, 2024	02/08
Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.	02/08	CI
ResMed Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2024	02/08	CI

ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (50.4%); - masks (37.9%); - software as a service (11.7%). At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia. The United States accounts for 61.4% of net sales.

Employees

9,980

Sector

Advanced Medical Equipment & Technology

Calendar

30/09/2024 - Investor Day

Related indices

S&P 500 , S&P/ASX 200

More about the company